Biohaven Ltd. has announced the commencement of a global Phase 2/3 clinical trial for their investigational drug, BHV-8000, aimed at treating early Parkinson's disease $(PD)$. BHV-8000 is a first-in-class, orally-administered inhibitor of TYK2 and JAK1 kinases, designed to penetrate the brain and target neuroinflammation and immune dysregulation associated with PD progression. The trial will assess the efficacy and safety of BHV-8000 at dosages of 10 mg and 20 mg, compared to a placebo, with a focus on time-to-event analysis based on the MDS-UPDRS Part II scale. The study will enroll 550 participants across 13 countries, including the United States, Canada, and several European nations. This trial seeks to address the current lack of approved disease-modifying therapies for Parkinson's disease, which affects over 10 million people worldwide. Further information is available at https://www.clinicaltrials.gov/study/NCT06976268.